RELiZORB is proven to hydrolyze available fats,* including medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs)

  • LCTs are extremely hard to hydrolyze
  • LCTs provide approximately 10% more calories than MCTs

>90%

fat hydrolysis* with RELiZORB

Greater than 90% of available fats hydrolyzed in most enteral formulas tested, including Nutren 2.0, Impact Peptide 1.5, Peptamen 1.5, Peptamen AF, and Nutren 1.0. Percentage of fat hydrolysis is estimated based on label claim for content, calculated using 500 mL of formula with a pump rate of 120 mL/hr. Formula manufacturers may change the composition of their formulas, which may affect the operation of RELiZORB. Please refer to formula product websites for recent product descriptions, ingredients, and nutritional information.

RELiZORB Is Specifically Designed to Deliver More Absorbable Calories from Enteral Formula

In controlled studies using a well-established porcine model of exocrine pancreatic insufficiency, RELiZORB increased plasma levels of omega-3 fats (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]).

Formula hydrolyzed with RELiZORB was associated with a statistically significant increase in total fat absorption and improvement in uptake of omega-3 fatty acids (DHA and EPA) in plasma level over 24 hours compared with non-hydrolyzed formula without RELiZORB (P<0.05).

RELiZORB use increased plasma levels of omega-3 (DHA and EPA) in preclinical studies.

RELiZORB normalized plasma levels of DHA and EPA in a controlled study using a well-established porcine model of exocrine pancreatic insufficiency, as seen in the figure below.

This chart shows RELiZORB normalized plasma levels of omega-3 fatty acids (DHA and EPA) in a controlled study using a well-established porcine model of exocrine pancreatic insufficiency. This chart shows RELiZORB normalized plasma levels of omega-3 fatty acids (DHA and EPA) using a well-established porcine model of exocrine pancreatic insufficiency.

The clinical significance of these observations has not been determined.

RELiZORB use enhanced fat absorption and caloric intake in preclinical studies, as demonstrated by improved plasma levels of DHA and EPA over 12 days.

DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) measured as ng/ml. Results are shown as a mean group ± SD.

Studies performed in a porcine model of exocrine pancreatic insufficiency. The clinical significance of these observations has not been determined.

§

P= 0.008 difference between RELiZORB vs. No RELiZORB for DHA.

P= 0.001.

Higher levels of fat-soluble vitamins (D and E) were observed with use of RELiZORB after 12 days.

This graph shows that use of RELiZORB within a well-established porcine model of exocrine pancreatic insufficiency resulted in higher levels of fat-soluble vitamins D & E.

Studies performed in a porcine model of exocrine pancreatic insufficiency. The clinical significance of these observations has not been determined.

Results are shown as a mean of group ± SD. #P<0.05 for difference between RELiZORB vs. No RELiZORB for vitamin D and vitamin E.

Formulas

The following formulas have been evaluated for use with RELiZORB and have demonstrated the hydrolysis levels shown below. Testing conditions were 500 mL of formula with a pump rate of 120 mL/hr.

This chart outlines several formulas that have been evaluated for use with RELiZORB and their demonstrated hydrolysis levels.

** % fat hydrolysis is estimated based on label claim fat content.

†† Fat hydrolysis rates are similar over the shelf life of RELiZORB.

Note: Formula manufacturers may change the composition of their formulas, which may affect the operation of RELiZORB. Please refer to formula product websites for recent product descriptions, ingredients, and nutritional information. If you have questions about whether your formula can be used with RELiZORB, please contact RELiZORB Support Services at 1-844-632-9271.

Close

This information is intended for
US healthcare professionals

Close
Close

You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.